Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Abeona Therapeutics Inc
ABEO | US
6.55
USD-0.12
-1.80%
ABEO | US
About Abeona Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
6.55
Open
6.67
High
6.74
Low
6.54
Abeona Therapeutics Inc. a clinical-stage biopharmaceutical company develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101 an autologous engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York New York.
View LessABEO | US
Risk
44.7
Sharpe
0.51
Luna's Score
42/100
Recommendation
Sell
Luna says (ABEO | US)
What's Working
Low Debt to Asset (< 0.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
35.8%1 month
44.7%3 months
50.4%6 months
99.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.99
Debt to equity
0.32
Debt to assets
0.17
Ent. to EBITDA
-0.58
Ent. to rev.
53.29
PEG
-
Other Fundamentals
EBITDA
-54.75M
MarketCap
283.71M
MarketCap(USD)
283.71M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-127.38
Short ratio
11.83
Short perc.
6.35
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.63
Range1M
1.09
Range3M
2.48
Volumes: Market Activity
Rel. volume
0.32
Price X volume
532.28K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.58 | - | Cheaper |
| Ent. to Revenue | 53.29 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.99 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 50.39 | - | Lower Risk |
| Debt to Equity | 0.32 | -1.23 | Expensive |
| Debt to Assets | 0.17 | 0.25 | Cheaper |
| Market Cap | 283.71M | - | Emerging |
